From Chemical to Drug – The Path to a Small Molecule IND
Presented by JLabs @NYC
Program Overview:
Do you have a solid plan to achieve IND acceptance? Filing an Investigational New Drug (IND) application might be the next step in advancing your company’s early-stage drug development program. Johnson & Johnson Innovation, JLABS and Janssen Discovery Sciences invite you to an in-depth look into the process of filing an IND. Whether your goal is to develop a pipeline through commercial launch or partner as early as possible, submitting an IND is a critical early milestone for every biotech company. With big Pharma and VC firms competing for the most promising compounds, startups are expected to demonstrate a clear blueprint for IND approval, and we want you to be ready.
The presentations will highlight the following:
- Janssen Research & Development – your partner of choice
- Preclinical Development strategies for pharmacokinetics, drug metabolism and toxicology
- Key CMC strategies to balance cost, time and quality risks
- Designing First-in-Human trials to highlight the qualities of your molecule
- Regulatory strategy, IND requirements, and Pre-IND meetings
Speakers
- Jim Tobin | VP of Cardiovascular & Metabolic Scientific Innovation
- Johnson & Johnson Innovation
- Mike Kelley | Sr. Scientific Director, Preclinical Development & Safety Janssen R&D
- Daniel Schaufelberger | Sr. Scientific Director, Portfolio Management, Janssen R&D
- Dolly Parasrampuria | Scientific Director, Janssen R&D
- Kathy Tsokas | Sr. Director, Global Regulatory Affairs, Janssen R&D
Fees:
$35 | General Public
$20 | Student/Academic
$45 | At the door
For full details and to register visit:
https://www.eventbrite.com/e/nyc-session-from-chemical-to-drug-the-path-to-a-small-molecule-ind-tickets-33489906211?aff=blast
